Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Nanobiotix met haar NBTXR3 richting €80,- in 2014 ? (Heden €17,-)
Volgen
Volume ok vandaag, vermoedelijk mag het nog niet uitbreken. Opening was goed om vervolgens gedurende handelsdag langzaam weg te zakken. Geduld..., geldt voor meer Franse Biotech deze periode.
Toch wil nano niet echt doorbreken. Blijft altijd maar kort boven de 20 euro om vervolgens weer terug te vallen. Geen verkeerd aandeel, maar het spektakel blijft telkens uit.
Nanobiotix receives thumbs up from City broker Stifel Share 08:08 03 Jul 2015 Broker Stifel's highly regarded healthcare team has repeated its bullish stance of the French nano-medical technology The broker Stifel repeated its ‘buy’ advice and its bullish price target on Nanobiotix (EPA:NANO), after the developer of nano-medical technology was given the go ahead to start two new cancer trials. Stifel, which reckons the stock is worth €30.10 (current price €17.95), said the authorisations reveal the company is on track with its development plans for the year. It was given clearance to start new clinical trials for its lead NanoXray product, NBTXR3, which will be used to treat patients with hepatocellular cancer (the most common liver cancer) and liver metastases. It brings to five the number of cancer studies Nanobiotix currently is currently running. The latest test will evaluate the use of NBTXR3 in conjunction with high precision radiation therapy, delivered as high dose fractions, known as Stereotatic Body Radiation Therapy (SBRT). SBRT is the safest and most modern radiotherapy currently available for the treatment of malignant liver tumours, but it has been shown to be efficient only in specific subsets of population with small tumours, and complete response is a rare event. Nanobiotix's lead NanoXray product, NBTXR3, is activated by radiotherapy and works by the deposit of increased energy doses (radio-enhancement) within the tumour. Nanobiotix's technology works by allowing radiotherapy to be administered in a very targeted and effective way, thus destroying more of the tumour. “Most cases of hepatocellular cancer or liver metastases are inoperable,” said Stifel analyst Michael King. “While radiation therapy has been shown to improve clinical outcomes, high doses are usually not possible, so the increase in energy doses provided by NBTXR3 could significantly improve efficacy.” Nanobiotix’s liver cancer trial has been supported by a broad NBTXR3 pre-clinical programme specific to these cancers, showing that the use of the product is feasible and well-tolerated in animals.
In ieder geval een mooi koersdoel van € 30,10 Eerder dit jaar ook al een koersdoelverhoging van Edison naar ruim € 34,- Het moet een keer gaan gebeuren voor Nanobiotix.
Er gebeurt jammer genoeg nog altijd nix..
Paris, France, le 27 août 2015 – NANOBIOTIX (Euronext : NANO – ISIN: FR0011341205), société française pionnière en nanomédecine développant NanoXray, une approche thérapeutique révolutionnaire pour le traitement local du cancer, annonce ses résultats consolidés audités pour le premier semestre 2015, arrêtés au 30 juin 2015. Informations financières · Le chiffre d’affaires total est d’environ 1,7 M€ (S1 2014 : 1 M€), correspondant à la quote-part du premier versement effectué par PharmaEngine (91K€), au Crédit d’impôt Recherche (1,4 M€) et autres subventions (149 K€) · Augmentation des coûts de R&D (6,1 M€ contre 3,3 M€ au 30 juin 2014) en support de l’accélération du plan de développement clinique, avec notamment l’expansion de l’essai pivot (phase II/III) pour le sarcome des tissus mous, l’étude tête et cou de phase I/II et la préparation de nouveaux essais cliniques · Augmentation des frais généraux à 2,8 M€ (S1 2014 : 1,8 M€) résultant principalement du développement du groupe, en ce compris notamment les analyses préparatoires à la mise sur le marché (market access) du produit NBTXR3, les projets de business development et les activités de la filiale américaine · La perte opérationnelle s’établit à -7,8 M€ (S1 2014 : -4,1 M€) sur la période, conformément aux prévisions · La trésorerie est de 25 M€ au 30 juin 2015 (S1 2014 : 27 M€) Principaux évènements opérationnels · Expansion de l’étude pivot avec NBTXR3 dans le sarcome des tissus mous (STM) à trois nouveaux pays européens et demandes d’approbation en cours dans d’autres pays d’Europe, en Asie et au Canada, conformément aux plans de la Société · Résultats préliminaires positifs de l’essai clinique de phase I/II dans les cancers de la tête et du cou avec le produit NBTXR3 · Recrutement de CordenPharma, nouveau partenaire pour la production afin d’augmenter la disponibilité du produit NBTXR3 en amont du marquage CE anticipé à fin 2016 · Professeur Robert Langer, Institute Professor au Massachusetts Institute of Technology (MIT), expert mondialement reconnu en nanomédecine et entrepreneur dynamique, devient Conseiller Scientifique de Nanobiotix Principaux évènements survenus depuis la clôture du premier semestre · Démarrage d’un essai clinique de Phase I/II pour NBTXR3 dans deux nouvelles indications : le carcinome hépatocellulaire (HCC) et les métastases du foie Laurent Levy, président du Directoire et co-fondateur de Nanobiotix déclare : « Nous avons réalisé des avancées significatives au cours des six derniers mois, particulièrement concernant le développement clinique de notre produit NBTXR3. Nous menons maintenant des essais cliniques dans 5 indications : le sarcome des tissus mous, le cancer de la tête et du cou, le cancer du rectum (par PharmaEngine) et les cancers du foie, ce qui témoigne bien de la transférabilité potentielle de l’usage de NBTXR3 dans différents types de cancers. Nous allons poursuivre l’extension du développement clinique de NBTXR3 en lançant d'autres indications comme par exemple le cancer de la prostate, prévu aux Etats-Unis d'ici la fin de l'année. La situation financière de Nanobiotix demeure solide et conforme aux prévisions de la Société. Les mois à venir devraient être productifs au regard de notre développement clinique, et nous sommes sur la bonne voie pour obtenir à la fin de l’année 2016, le marquage CE pour notre produit leader, dans le sarcome des tissus mous. »
Is er nieuws? opeens flink omhoog.
Geen nieuws gezien Omnius, maar een keer een correctie naar boven is wel logisch gezien de daling van de laatste tijd. De vooruitzichten zijn goed, kaspositie is in orde en er zijn 2 koersdoelen boven de € 30,- Het is nu te hopen dat het weer eens doorzet.
Dat idee had ik ook, maar vond de stijging vrij fors en volume ook t.o.v. normaal. Heb er verder niet veel van in porto, maar was benieuwd of er een aanleiding voor de stijging was. thnx
Ik hang het op aan terugkerend algemeen positief biotech sentiment, hierin kan Nanobiotix niet ontbreken;-)
Mee eens Laugh about it, dit speelt zeker mee. En wat mogelijk ook nog meespeelt is de kans op overnames binnen de biotechnologie. Kijk eens naar Cellectis, in een week tijd. Ik schreef hier al een paar keer over. Vorige week woensdag nog een slot van € 22,43 en gisteren een slot van € € 32,30. Ik ben zelf gisteren uit Cellectis gestapt met een hele mooie winst maar als ik naar de opening kijk had ik nog wel kunnen blijven zitten. hopelijk gaat Nano eenzelfde sprong maken. Mijn positie in Nano hou ik voorlopig vast en ik hoop Cellectis over een tijdje weer lager te kunnen kopen.
Nog ideeen over 2016?; 2015 was niet top voor nano
www.nanobiotix.com/news/release/fda-a... FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer 01.04.2016 Paris France, Cambridge MA, USA, January 4th, 2016 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the US Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application on the 30th of December. This allows Nanobiotix to launch its first clinical study in the US for its lead product NBTXR3 in prostate cancer, a new and very significant indication. The FDA approval enables the Company to initiate a phase I/II prospective, open-label, two cohorts and non-randomized trial, in the large prostate cancer patient population. The first part of the trial should involve departments of radiation oncology of from three reference US oncology centers. Nanobiotix is seeking to develop NBTXR3 for patients with intermediate and high-risk prostate cancer, with the aim of providing effective tumor destruction and disease control. Prostate cancer is the second most common form of cancer in the US among the male population: one out of seven men will be diagnosed with prostate cancer, and it is the second leading cause of cancer death (American Cancer Society). Efficient local control is key for treatment of the primary prostate tumor to prevent relapse and subsequent spreading of the disease (metastasis). Radiotherapy is used for that purpose, but presents limitations in such patient population. The importance of the delivered energy dose in improving disease outcome has been extensively demonstrated. More precisely literature data have shown that increasing the radiotherapy energy dose significantly improve the local control and decrease the distant failure. NBTXR3 is a nano-sized radio-enhancer that operates at the tumor level, bound and captured by cancer cells. Using NBTXR3 in combination with radiotherapy may significantly open the therapeutic window and improve efficacy by increasing the energy dose deposit within the malignant tissues, without adding toxicity to surrounding healthy tissues. Laurent Levy, Nanobiotix CEO commented: “The FDA approval opens the regulatory pathway for our lead product NBTXR3 in the US, the largest market for cancer therapeutics. Expansion in new indications and global development of NBTXR3 are key to establish this technology as a new standard of care”. In addition to the prostate cancer trial, Nanobiotix is currently running trials in five indications across Europe and the Asia-Pacific Region: a registration trial in soft tissue sarcoma and Phase I/II trials in liver cancers (HCC and liver metastases), head and neck cancers and rectal cancer (in Asia by Nanobiotix’s partner PharmaEngine). -Ends-
Gaat dit dan eindelijk het jaar van Nanobiotix worden? Ik heb er alle vertrouwen in en de nieuwsberichten zijn er alvast dit jaar. Nanobiotix starts a new research program in Immuno Oncology with its lead product NBTXR3 01.05.2016 Paris, Cambridge, January 5, 2016 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. Elsa Borghi, Nanobiotix’s Medical Director, commented: “With six ongoing indications, our global clinical development of NBTXR3 as a radio-enhancer, is progressing well. This Immuno Oncology program could bring new applications and confirm that additional patient populations could benefit from treatment with NBTXR3”. NBTXR3 current clinical development NBTXR3 is a radio-enhancer, using a physical mode of action to destroy cancer cells in any solid tumors, in combination with radiotherapy. Nanobiotix is running a global clinical development program with its lead product NBTXR3, in six indications across Europe, the US and the Asia-Pacific Region: a registration trial in soft tissue sarcoma, and Phase I/II trials in liver cancers (HCC and liver metastases), prostate cancer, head and neck cancer and rectal cancer (in Asia by Nanobiotix’s partner PharmaEngine). In situ (intratumoral) vaccination with NBTXR3 opens new potential prospects in Immuno Oncology The aim of Immuno Oncology (IO) is to boost patients’ immune systems to fight cancer, through different approaches. It is very efficient for a limited number of patients whose tumors have natural and sufficient immunogenicity. However, to exploit the full potential of immune therapies it is necessary to increase this immunogenicity at tumor level. Indeed, it has been demonstrated that radiotherapy can be used to improve immunogenicity, by creating Immunogenic Cell Death (ICD) in many situations. NBTXR3 nanoparticles’ activation enhances the energy deposited where they are injected, improving the cancer cell death and efficacy of radiotherapy. This technology is based on physics and can potentially be applied across all radiotherapy indications. All preclinical model have shown a systematic superiority of cell killing, when using NBTXR3 with radiotherapy, compared to radiotherapy alone. Hence, NBTXR3 could have the potential to be used as an in situ (intratumoral) vaccination that would create ICDs which, in turn, could bring a new dimension and broaden the usage of immuno therapies in oncology. To explore this brand new field of development opportunities, the Company has launched a pre-clinical development program.
Er begint weer beweging in het aandeel te komen. De verwachtingen voor dit jaar zijn hoog en zoals CEO Levy aan heeft gegeven was de belangrijkste zaak van vorig jaar meer bekend worden en werken aan productontwikkeling. Het ziet er naar uit dat dit een mooi jaar gaat worden. de koers werkt de laatste dagen in ieder geval weer mee. Op 20 januari een dieptepunt van € 12,39 maar inmiddels weer ruim boven de € 16,- Er zijn twee koersdoelen die beiden boven de € 30,- staan. Potentie genoeg nu nog afwachten of het dit jaar word waargemaakt.
Vandaag weer mooie berichten over Nanobiotix. Gilbert Dupont geeft een koersdoel voor 12 maanden van € 31,- en voor de verdere toekomst zelfs mogelijkheden tot € 131,- Uiteraard afhankelijk van de opbrengsten van de behandelingen. Maar feit is wel dat de vooruitzichten erg goed zijn en met sprongen vooruit gaan. Ook in de huidige koers is te zien dat er meer vertrouwen komt. 21 januari stond de koers nog op € 13,02 en inmiddels ruim boven de € 17,-
Op 29 april is Nanobiotix met haar cijfers gekomen over 2015. Naar aanleiding hiervan heeft Gilbert Dupont Het koersdoel vandaag gezet op € 42,90. De koers staat op dit moment ongeveer 5 % hoger, iets boven de € 18,- Een mooi moment om in te stappen of bij te kopen. Zelf zit ik er al behoorlijk in en zie ook de mogelijkheden voor Nanobiotix.
Geweldig nieuws van Nanobiotix! Ik geef al een tijd aan dat dit volgens mij een bedrijf is met veel mogelijkheden en dit onderstaande bericht geeft hier weer een bevestiging van. Zoals eerder gemeld zit ik er zelf behoorlijk in, maar blijf altijd objectief. Verdiep je in het aandeel en doe er je voordeel mee. Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology 05.31.2016 Paris, France, Cambridge, MA, USA May 31, 2016 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept (POC) with the lead product NBTXR3 for its new program in Immuno Oncology (IO). Delivering first promising data with its Immuno Oncology preclinical program, showing the potential to turn the tumor itself into a vaccine using NBTXR3 Creating a potential new usage and new market for NBTXR3 in parallel to its mainstream clinical development Providing new opportunities by combining NBTXR3 with other Immuno Oncology drugs with a unique competitive advantage Immuno-oncology works by boosting patients’ immune systems to recognise and attack tumours and therefore, kill the cancer. The approach is very efficient for a limited number of patients whose tumors have the ability to provoke an immune response i.e. they have a natural and sufficient immunogenicity, and are referred to as ‘hot’ tumors. However, in many patients, the tumours are ‘cold’ and the therapeutic approach has little response. To be able to expand the number of patients that can respond to IO, thereby exploiting its full potential, immunogenicity needs to be increased at the tumor level. Nanobiotix’s approach to achieve this is to trigger Immunogenic Cell Death (ICD) at the tumor level, transforming “cold tumors” into “hot tumors”. Preliminary in vitro and in vivo preclinical data suggest that Nanobiotix’s radioenhancer NBTXR3 might be used, not only to destroy tumors (as it is currently being clinically developed), but also to enhance the power of radiotherapy to create intratumoral vaccines for IO, and convert ‘cold’ tumours to ‘hot’. NBTXR3 current clinical development to destroy tumors and provide better local control of cancer NBTXR3 is a radio-enhancer, using a physical mode of action to destroy cancer cells in any solid tumors, in combination with radiotherapy. Nanobiotix is running a global clinical development program with its lead product NBTXR3, in six indications across Europe, the US and the Asia-Pacific Region: a registration trial in soft tissue sarcoma, and Phase I/II trials in liver cancers (HCC and liver metastases), prostate cancer, head and neck cancer and rectal cancer (in Asia by Nanobiotix’s partner PharmaEngine). New usage of NBTXR3 for in situ (intratumoral) vaccination opening new potential prospects in Immuno Oncology: preliminary preclinical proof of concept NBTXR3 nanoparticles’ activation by radiation enhances the energy deposited where they are injected, improving cancer cell death and the efficacy of radiotherapy. This technology is based on physics and can potentially be applied across all radiotherapy indications. All preclinical model (in vitro and in vivo) have shown a systematic superiority of cell killing, when using NBTXR3 with radiotherapy, compared to radiotherapy alone.
Geweldig nieuws van Nanobiotix. Gaat vandaag de klapper worden op de beurs!!www.nanobiotix.com/download/news_en/2...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
900,06
+1,00%
EUR/USD
1,0750
-0,18%
FTSE 100
8.313,67
+1,22%
Germany40^
18.444,40
+0,08%
Gold spot
2.315,40
+0,06%
NY-Nasdaq Composite
16.332,56
-0,10%
Stijgers
Dalers